Date | Panel | Item | Activity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wilms Tumour v0.40 | NYNRIN | Zornitza Stark Marked gene: NYNRIN as ready | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Wilms Tumour v0.40 | NYNRIN | Zornitza Stark Gene: nynrin has been classified as Amber List (Moderate Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Wilms Tumour v0.33 | NYNRIN | Chirag Patel Classified gene: NYNRIN as Amber List (moderate evidence) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Wilms Tumour v0.33 | NYNRIN | Chirag Patel Gene: nynrin has been classified as Amber List (Moderate Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Wilms Tumour v0.32 | NYNRIN |
Chirag Patel gene: NYNRIN was added gene: NYNRIN was added to Wilms Tumour. Sources: Expert list,Expert Review,Literature Mode of inheritance for gene: NYNRIN was set to BIALLELIC, autosomal or pseudoautosomal Publications for gene: NYNRIN were set to PMID: 30885698 Phenotypes for gene: NYNRIN were set to Wilms tumor, MONDO:0006058; Wilms tumour, no MIM# Review for gene: NYNRIN was set to AMBER Added comment: Some evidence for gene-disease association for Wilms tumour. Three cases of biallelic truncating variants associated with sporadic Wilms tumour. Sources: Expert list, Expert Review, Literature |